Ratings Chaoju Eye Care Holdings Limited

Equities

2219

KYG2047K1094

Market Closed - Hong Kong S.E. 01:39:00 03/05/2024 pm IST 5-day change 1st Jan Change
3.96 HKD +3.66% Intraday chart for Chaoju Eye Care Holdings Limited +5.88% -10.41%

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 65% by 2026.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company returns high margins, thereby supporting business profitability.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analyst opinion has improved significantly over the past four months.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
-10.41% 342M -
-18.46% 16.57B
B+
+4.50% 12.51B
B
+4.31% 11.69B
B+
+5.36% 10.36B
B+
+24.72% 8.38B
B
-2.64% 7.75B
A-
+19.32% 7.16B
D
+4.17% 6.6B
B-
+46.90% 4.54B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2219 Stock
  4. Ratings Chaoju Eye Care Holdings Limited